Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Orlando Marchena Arraut

Internal Medicine Ponce, PR Medical Doctor

NPI 1831114719 CMS profile 1298846

2445 Avenida Las Americas, Ste 102, Ponce, PR 00717

Open in the dashboard

General payments

$847

25 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Orlando Marchena Arraut of Ponce, PR is reported in the CMS Open Payments database as having received $847 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $51 1
2024 General $194 2
2022 General $184 4
2021 General $6 1
2020 General $34 5
2019 General $378 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Orlando Marchena Arraut
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Orlando Marchena Arraut were reported at $51. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Orlando Marchena Arraut Internal Medicine median Middle half National median
2019 $378 $159 $48–$570 $163
2020 $34 $119 $33–$402 $114
2021 $6 $135 $37–$521 $132
2022 $184 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $194 $154 $47–$537 $164
2025 $51 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $203 2 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $131 2 payments
  3. E.R. Squibb & Sons, L.L.C. $91 3 payments
  4. Lilly USA, LLC $91 2 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $77 8 payments
  6. Medtronic, Inc. $61 1 payment
  7. Janssen Pharmaceuticals, Inc $58 3 payments
  8. KCI USA, Inc $55 1 payment
  9. GlaxoSmithKline, LLC. $51 1 payment
  10. Amgen Inc. $16 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $847 25 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN FLX $133 1 payment
  2. ELIQUIS $91 3 payments
  3. JARDIANCE $84 1 payment
  4. LifeVest $77 8 payments
  5. WATCHMAN $70 1 payment
  6. SYMPLICITY G3 $61 1 payment
  7. XARELTO $58 3 payments
  8. PREVENA $55 1 payment
  9. VAC VERAFLO $55 1 payment
  10. SNAP $55 1 payment
  11. Other $139 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 87 drugs

Part D claims

5,657

Median for Internal Medicine: 777

Drug cost

$206,075

Median for Internal Medicine: $73,373

Branded share of claims

16.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jentadueto Linagliptin/Metformin Hcl Brand 86 $48,543
Januvia Sitagliptin Phosphate Brand 31 $19,414
Jardiance Empagliflozin Brand 29 $17,965
Eliquis Apixaban Brand 34 $17,759
Janumet Sitagliptin Phos/Metformin Hcl Brand 23 $12,769
Tradjenta Linagliptin Brand 14 $9,403
Synthroid Levothyroxine Sodium Brand 111 $6,369
Synjardy Empagliflozin/Metformin Hcl Brand 13 $4,615
Humulin N Insulin Nph Human Isophane Brand 65 $4,578
Raloxifene Hcl Generic 112 $4,393

The 10 drugs with the highest cost, of 87 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record